Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Clinical trial NCT07022483 · RECRUITING

Trial details

NCT number: NCT07022483
Sponsor: Daiichi Sankyo
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Endometrial Cancer

Start date: 2025-09-30
Primary completion: 2032-03-23
Enrollment: 710

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.